专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007041680A2 THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM 审中-公开
标题翻译：心力衰竭的遗传风险评估：β1肾上腺素能受体GLY389ARG多态性遗传变异的影响
公开(公告)号：WO2007041680A2
公开(公告)日：2007-04-12
申请号：PCT/US2006038964
申请日：2006-10-04
申请人： NITROMED INC , UNIV PITTSBURGH , WORCEL MANUEL , SABOLINSKI MICHAEL L , TAM SANG WILLIAM , MCNAMARA DENNIS M
发明人： WORCEL MANUEL , SABOLINSKI MICHAEL L , TAM SANG WILLIAM , MCNAMARA DENNIS M
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K31/34 , A61K31/502 , A61K45/06 , C12Q2600/106 , C12Q2600/156 , A61K2300/00
摘要： The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B- type natriuretic protein; (1) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a Arg389Arg polymorphism and/or a Gly389Gly polymorphism in the beta 1 adrenergic receptor gene, compiising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.
摘要翻译：本发明提供了用于（a）降低与心力衰竭相关的死亡率的方法; （b）改善耗氧量; （c）治疗心力衰竭; （d）治疗高血压; （e）提高心力衰竭患者的生活质量; （f）抑制左心室重构; （g）减少与心力衰竭有关的住院治疗; （h）提高运动耐力; （j）增加左心室射血分数; （k）B型利钠肽蛋白水平降低; （1）治疗肾血管性疾病; （m）治疗终末期肾脏疾病; （n）减少心脏肿大; （o）治疗由氧化应激引起的疾病; （p）治疗内皮功能障碍; （q）治疗由内皮功能障碍引起的疾病; 或（r）治疗心血管疾病; 其中所述患者在所述β1肾上腺素能受体基因中具有Arg389Arg多态性和/或Gly389Gly多态性，包括向所述患者施用（i）至少一种抗氧化剂化合物或其药学上可接受的盐; （ii）至少一种一氧化氮增强化合物; 和（iii）任选地用于治疗心血管疾病的最佳当前疗法。在一个实施方案中，所述抗氧化剂是肼屈嗪化合物或其药学上可接受的盐，并且所述一氧化氮增强化合物是二硝酸异山梨酯和/或单硝酸异山梨酯。

2. 发明申请

WO2007041676A3 THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM 审中-公开
公开(公告)号：WO2007041676A3
公开(公告)日：2007-04-12
申请号：PCT/US2006/038956
申请日：2006-10-04
申请人： NITROMED, INC. , UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION , WORCEL, Manuel , SABOLINSKI, Michael, L. , TAM, Sang, William , McNAMARA, Dennis, M.
发明人： WORCEL, Manuel , SABOLINSKI, Michael, L. , TAM, Sang, William , McNAMARA, Dennis, M.
IPC分类号： C12Q1/68
摘要： The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (Ic) decreasing levels of B-type natriuretic protein; (1) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a -344 (T/T) polymorphism or a -344 (C/C) polymorphism in an aldosterone synthase CYPl1B2 gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.

3. 发明申请

WO2007041676A2 THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM 审中-公开
标题翻译：心脏遗传危险评估：ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM遗传变异的影响
公开(公告)号：WO2007041676A2
公开(公告)日：2007-04-12
申请号：PCT/US2006038956
申请日：2006-10-04
申请人： NITROMED INC , UNIV PITTSBURGH , WORCEL MANUEL , SABOLINSKI MICHAEL L , TAM SANG WILLIAM , MCNAMARA DENNIS M
发明人： WORCEL MANUEL , SABOLINSKI MICHAEL L , TAM SANG WILLIAM , MCNAMARA DENNIS M
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172
摘要： The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (Ic) decreasing levels of B-type natriuretic protein; (1) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a -344 (T/T) polymorphism or a -344 (C/C) polymorphism in an aldosterone synthase CYPl1B2 gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.
摘要翻译：本发明提供了（a）降低与心力衰竭相关的死亡率的方法; （b）改善耗氧量; （c）治疗心力衰竭; （d）治疗高血压; （e）改善心力衰竭患者的生活质量; （f）抑制左心室重构; （g）减少与心力衰竭相关的住院; （h）提高运动耐力; （j）增加左室射血分数; （Ic）降低B型利尿钠蛋白水平; （1）治疗血管性疾病; （m）治疗终末期肾病; （n）减轻心脏肥大; （o）治疗由氧化应激引起的疾病; （p）治疗内皮功能障碍; （q）治疗由内皮功能障碍引起的疾病; 或（r）治疗心血管疾病; 在有需要的患者中，其中所述患者在醛固酮合酶CYP1B2基因中具有-344（T / T）多态性或-344（C / C）多态性，其包括给予所述患者（i）至少一种抗氧化剂化合物或其药学上可接受的盐; （ii）至少一种一氧化氮增强化合物; 和（iii）任选的治疗心血管疾病的最佳治疗方法。在一个实施方案中，抗氧化剂是肼屈嗪化合物或其药学上可接受的盐，一氧化氮增强化合物是硝酸异山梨酯和/或单硝酸异山梨酯。

4. 发明申请

WO2007041680A3 THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM 审中-公开
公开(公告)号：WO2007041680A3
公开(公告)日：2007-04-12
申请号：PCT/US2006/038964
申请日：2006-10-04
申请人： NITROMED, INC. , UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION , WORCEL, Manuel , SABOLINSKI, Michael, L. , TAM, Sang, William , McNAMARA, Dennis, M.
发明人： WORCEL, Manuel , SABOLINSKI, Michael, L. , TAM, Sang, William , McNAMARA, Dennis, M.
IPC分类号： A01N43/58
摘要： The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B- type natriuretic protein; (1) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a Arg389Arg polymorphism and/or a Gly389Gly polymorphism in the beta 1 adrenergic receptor gene, compiising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式